Results 141 to 150 of about 12,578,124 (406)

Circulating tumor DNA (ctDNA) trajectories predict survival in trifluridine/tipiracil‐treated metastatic colorectal cancer patients

open access: yesMolecular Oncology, EarlyView.
The authors applied joint/mixed models that predict mortality of trifluridine/tipiracil‐treated metastatic colorectal cancer patients based on circulating tumor DNA (ctDNA) trajectories. Patients at high risk of death could be spared aggressive therapy with the prospect of a higher quality of life in their remaining lifetime, whereas patients with a ...
Matthias Unseld   +7 more
wiley   +1 more source

Orthotopic liver transplantation in children. Two-year experience with 47 patients [PDF]

open access: yes, 1984
During a 24-month period (May 1981 to May 1983), 47 pediatric patients (ranging in age from 7 months to 18 years) underwent orthotopic liver transplantation using cyclosporine and prednisone.
Gartner, JC   +5 more
core  

The use of ultrasound in clinical setting for children affected by NAFLD. is it safe and accurate? [PDF]

open access: yes, 2011
Non-alcoholic fatty liver disease (NAFLD) has become over the last decade the most common form of chronic liver disease in children and adults. Thus, establishing the diagnosis of NAFLD is of utmost importance and represents a major challenge as the ...
Alisi A   +4 more
core   +3 more sources

Epigenetics in liver disease [PDF]

open access: yesHepatology, 2014
Epigenetics is a term that encompasses a variety of regulatory processes that are able to crosstalk in order to influence gene expression and cell phenotype in response to environmental cues. A deep understanding of epigenetics offers the potential for fresh insights into the basis for complex chronic diseases and improved ...
openaire   +4 more sources

Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer

open access: yesMolecular Oncology, EarlyView.
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia   +17 more
wiley   +1 more source

Development of a decision support tool to facilitate primary care management of patients with abnormal liver function tests without clinically apparent liver disease [HTA03/38/02]. Abnormal Liver Function Investigations Evaluation (ALFIE) [PDF]

open access: yes, 2007
Liver function tests (LFTs) are routinely performed in primary care, and are often the gateway to further invasive and/or expensive investigations.
A Desgagne   +35 more
core   +7 more sources

Global burden of Liver Disease: 2023 Update.

open access: yesJournal of Hepatology, 2023
H. Devarbhavi   +5 more
semanticscholar   +1 more source

Prescribing in liver disease

open access: yesMedicine, 2002
Patients with liver disease often require drug therapy. Since the liver is the main site of drug detoxification and elimination in the body, each patient's need for therapy must be carefully assessed; the choice of drug, its dose, and duration of therapy must be carefully considered in order to avoid adverse effects.
openaire   +2 more sources

Peripheral blood proteome biomarkers distinguish immunosuppressive features of cancer progression

open access: yesMolecular Oncology, EarlyView.
Immune status significantly influences cancer progression. This study used plasma proteomics to analyze benign 67NR and malignant 4T1 breast tumor models at early and late tumor stages. Immune‐related proteins–osteopontin (Spp1), lactotransferrin (Ltf), calreticulin (Calr) and peroxiredoxin 2 (Prdx2)–were associated with systemic myeloid‐derived ...
Yeon Ji Park   +6 more
wiley   +1 more source

Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. [PDF]

open access: yes, 2019
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses ...
Fong, Lawrence   +2 more
core   +2 more sources

Home - About - Disclaimer - Privacy